Wellington Management Group LLP trimmed its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 42.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 653,920 shares of the company's stock after selling 491,386 shares during the quarter. Wellington Management Group LLP owned about 1.25% of Axsome Therapeutics worth $160,060,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Kemnay Advisory Services Inc. acquired a new stake in Axsome Therapeutics during the fourth quarter worth approximately $31,000. Hollencrest Capital Management raised its holdings in Axsome Therapeutics by 400.0% in the 1st quarter. Hollencrest Capital Management now owns 200 shares of the company's stock valued at $34,000 after acquiring an additional 160 shares in the last quarter. Ameriflex Group Inc. acquired a new position in Axsome Therapeutics in the 4th quarter valued at $37,000. Advisory Services Network LLC bought a new stake in shares of Axsome Therapeutics during the 3rd quarter valued at $40,000. Finally, Farther Finance Advisors LLC lifted its position in shares of Axsome Therapeutics by 602.6% during the 4th quarter. Farther Finance Advisors LLC now owns 274 shares of the company's stock valued at $50,000 after acquiring an additional 235 shares during the period. Institutional investors and hedge funds own 81.49% of the company's stock.
Insider Transactions at Axsome Therapeutics
In other Axsome Therapeutics news, CFO Nick Pizzie sold 33,000 shares of the stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $240.09, for a total value of $7,922,970.00. Following the completion of the transaction, the chief financial officer directly owned 42,867 shares in the company, valued at approximately $10,291,938.03. This trade represents a 43.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Herriot Tabuteau sold 49,670 shares of Axsome Therapeutics stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $241.01, for a total value of $11,970,966.70. Following the sale, the chief executive officer directly owned 7,229 shares in the company, valued at $1,742,261.29. The trade was a 87.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 183,229 shares of company stock valued at $42,666,176. 20.60% of the stock is currently owned by corporate insiders.
Axsome Therapeutics Stock Down 0.3%
Shares of NASDAQ:AXSM opened at $198.52 on Tuesday. The company has a fifty day moving average of $226.44 and a 200-day moving average of $206.99. The company has a market capitalization of $10.40 billion, a PE ratio of -52.94 and a beta of 0.65. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.34 and a current ratio of 1.43. Axsome Therapeutics, Inc. has a 52-week low of $112.90 and a 52-week high of $260.19.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.99) EPS for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.10). The firm had revenue of $218.38 million during the quarter, compared to the consensus estimate of $221.11 million. Axsome Therapeutics had a negative net margin of 24.68% and a negative return on equity of 265.55%. On average, equities analysts predict that Axsome Therapeutics, Inc. will post -2.8 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts recently weighed in on the stock. Wells Fargo & Company upped their price objective on shares of Axsome Therapeutics from $255.00 to $256.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 11th. Truist Financial raised shares of Axsome Therapeutics to a "strong-buy" rating in a report on Monday, June 15th. Needham & Company LLC boosted their target price on shares of Axsome Therapeutics from $267.00 to $268.00 and gave the company a "buy" rating in a research report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft set a $280.00 price target on shares of Axsome Therapeutics in a report on Tuesday, May 5th. Finally, Morgan Stanley increased their price target on shares of Axsome Therapeutics from $242.00 to $251.00 and gave the stock an "equal weight" rating in a research report on Tuesday, August 11th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $267.60.
Get Our Latest Stock Report on AXSM
Axsome Therapeutics Company Profile
(
Free Report)
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.
Axsome's pipeline includes several late-stage and approved product candidates.
See Also
Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
